<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04056481</url>
  </required_header>
  <id_info>
    <org_study_id>ALN-AS1-005</org_study_id>
    <nct_id>NCT04056481</nct_id>
  </id_info>
  <brief_title>Expanded Access Protocol of Givosiran for Patients With Acute Hepatic Porphyria</brief_title>
  <official_title>Expanded Access Protocol of Givosiran for Patients With Acute Hepatic Porphyria (AHP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alnylam Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alnylam Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to provide expanded access of givosiran to patients with Acute
      Hepatic Porphyria (AHP).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Choosing to participate in an expanded access program is an important personal decision. Talk
      with your doctor and family members or friends about deciding to join a research study. To
      learn more about this study, please have your doctor contact the study research staff using
      the Contacts provided. For general information, see the link provided in More Information.
    </textblock>
  </detailed_description>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <expanded_access_info>
    <expanded_access_type_treatment>Yes</expanded_access_type_treatment>
  </expanded_access_info>
  <condition>Acute Hepatic Porphyria</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Givosiran</intervention_name>
    <description>givosiran (ALN-AS1) administered as a subcutaneous (SC) injection</description>
    <other_name>ALN-AS1</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with Acute Hepatic Porphyria (Acute Intermittent Porphyria, Hereditary
             Coproporhyria, Variegate Porphyria, ALA dehydratase deficient porphyria)

          -  Experienced a porphyria attack and be considered by their treating physician to be at
             risk for having an attack in the future.

          -  Have adequate venous access for program sample collections as judged by the
             Investigator for study sample collections

        Exclusion Criteria:

          -  Previously or currently participating in a givosiran clinical trial

          -  Has any of the following laboratory parameter assessments at Screening:

               1. Alanine aminotransferase (ALT) &gt;2×ULN

               2. Total bilirubin &gt;1.5×ULN. Patients with elevated total bilirubin that is
                  secondary to documented Gilbert's syndrome are eligible if the total bilirubin is
                  &lt;2×ULN

               3. Estimated Glomerular Filtration Rate (eGFR) &lt;30 mL/min/1.73 m2

          -  On an active liver transplantation waiting list
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Alnylam Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alnylam EAP Hotline</last_name>
    <phone>1-877-256-9526</phone>
    <email>eap@alnylam.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Program Site</name>
      <address>
        <city>Camperdown</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Program Site</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Program Site</name>
      <address>
        <city>Richmond</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Program Site</name>
      <address>
        <city>Sydney</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Program Site</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Program Site</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Program Site</name>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Program Site</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Program Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Program Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Program Site</name>
      <address>
        <city>Palma</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Program Site</name>
      <address>
        <city>Pamplona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Program Site</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Program Site</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Sweden</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>https://www.alnylam.com/medical-professional-resources/early-access-program/givosiran/</url>
    <description>Information on the Early Access Program for Givosiran</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>August 12, 2019</study_first_submitted>
  <study_first_submitted_qc>August 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2019</study_first_posted>
  <last_update_submitted>July 9, 2020</last_update_submitted>
  <last_update_submitted_qc>July 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Hepatic Porphyria (AHP)</keyword>
  <keyword>Acute Intermittent Porphyria (AIP)</keyword>
  <keyword>Porphyria</keyword>
  <keyword>Acute Intermittent</keyword>
  <keyword>Acute Porphyria</keyword>
  <keyword>Hereditary Coproporphyria (HCP)</keyword>
  <keyword>Variegate Porphyria (VP)</keyword>
  <keyword>ALA Dehydratase Deficient Porphyria (ADP)</keyword>
  <keyword>Givosiran</keyword>
  <keyword>Expanded Access</keyword>
  <keyword>EAP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Porphyrias, Hepatic</mesh_term>
    <mesh_term>Coproporphyria, Hereditary</mesh_term>
    <mesh_term>Porphyria, Erythropoietic</mesh_term>
    <mesh_term>Porphyrias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

